SCHEMBL15859876

SCHEMBL15859876

CC(=O)c1cc2cc(NCc3cc(NC(=O)c4ccc(CN5CCC(N(C)C)C5)c(C(F)(F)F)c4)ccc3C)cnc2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSK P41240 3/20 0.58
▸ MAPK14 Q16539 3/20 0.58
▸ ABL1 P00519 11/20 0.58
▸ BCR P11274 8/20 0.58
▸ LYN P07948 4/20 0.57
▸ BRAF P15056 3/20 0.57
▸ LCK P06239 2/20 0.57
▸ FYN P06241 2/20 0.57
▸ FRK P42685 2/20 0.57
▸ DDR1 Q08345 2/20 0.57
▸ EPHA2 P29317 2/20 0.57
▸ MAP3K20 Q9NYL2 2/20 0.57
▸ RIPK2 O43353 1/20 0.57
▸ RET P07949 1/20 0.57
▸ PDGFRB P09619 1/20 0.57
▸ ARAF P10398 1/20 0.57
▸ NQO2 P16083 1/20 0.57
▸ EPHB2 P29323 1/20 0.57
▸ ABL2 P42684 1/20 0.57
▸ MAPKAPK2 P49137 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17420203 1.00 CSK (0.58) CSKMAPK14ABL1BCRLYN
SCHEMBL15859845 1.00 CSK (0.58) CSKMAPK14ABL1BCRLYN
SCHEMBL15859830 0.95 CSK (0.58) CSKMAPK14ABL1BCRLYN
SCHEMBL3714894 0.95 CSK (0.58) CSKMAPK14ABL1BCRLYN
SCHEMBL15859883 0.95 CSK (0.58) CSKMAPK14ABL1BCRLYN
SCHEMBL15859847 0.95 CSK (0.57) CSKMAPK14ABL1BCRLYN
SCHEMBL17420204 0.95 CSK (0.57) CSKMAPK14ABL1BCRLYN
SCHEMBL15859819 0.95 CSK (0.57) CSKMAPK14ABL1BCRLYN
SCHEMBL15372817 0.94 CSK (0.60) CSKMAPK14ABL1BCRLYN
SCHEMBL17420231 0.94 CSK (0.60) CSKMAPK14ABL1BCRLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9403823-B2 Protein kinase inhibitors ORIBASE PHARMA (FR) 2016-08-02 — — US disclosed
US-20160009709-A1 PROTEIN KINASE INHIBITORS ORIBASE PHARMA (FR) 2016-01-14 — — US disclosed
WO-2014102376-A1 PROTEIN KINASE INHIBITORS ORIBASE PHARMA (FR) 2014-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009709-A1 PROTEIN KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K2 CSK 131/4885MAPK14 78/4885ABL1 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback